scholarly journals Effectiveness of heat and moisture exchangers in preventing ventilator-associated pneumonia in critically ill patients: a meta-analysis

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Mayra Gonçalves Menegueti ◽  
Maria Auxiliadora-Martins ◽  
Altacílio Aparecido Nunes
2012 ◽  
Vol 45 (12) ◽  
pp. 1295-1300 ◽  
Author(s):  
M. Auxiliadora-Martins ◽  
M.G. Menegueti ◽  
E.A. Nicolini ◽  
G.C. Alkmim-Teixeira ◽  
F. Bellissimo-Rodrigues ◽  
...  

2021 ◽  
Author(s):  
Yue-chen Sun ◽  
Chen-yi Wang ◽  
Hai-li Wang ◽  
Yao Yuan ◽  
Jian-hong Lu ◽  
...  

Abstract Introduction: Probiotic may have a role in prevention of ventilator-associated pneumonia (VAP) among mechanically ventilated patients, but the efficacy and safety remains inconsistent. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of probiotic (prebiotic, synbiotic) versus placebo in preventing VAP in critically ill patients undergoing mechanical ventilation. Methods: PubMed, Embase and the Cochrane library databases were searched to 10 October 2021 without language restriction for randomized or semi-randomized controlled trials evaluating probiotic (prebiotic, synbiotic) vs. placebo in prevention of VAP in critically ill mechanically ventilated patients. The pooled relative risk (RR) along with 95% confidence intervals (CI) were combined using a random-effects model. Furthermore, the trial sequential analysis (TSA) and subgroup analyses were performed. Statistical significance was regarded as P <0.05. Results: Twenty-three trials involving 5543 patients were eligible for meta-analysis. The combined RR of decreasing the risk of VAP by probiotic was 0.67 (0.56, 0.81) for all eligible studies, 0.69 (n =5136; 95% CI=0.57 to 0.84; P<0.01) for adults studies and 0.55 (n=407; 95%CI=0.31 to 0.99; P=0.046) for neonates/children studies. Additionally, the above-mentioned positive finding was verified by the result of TSA, subgroup analyses and cumulative meta-analysis in adult patients. Ample evidence demonstrated the existence of a 31% decrease in RR of incidence of VAP when prophylactic probiotic therapy was administrated among adult patients. Finally, there were no effects on the ICU/hospital/28-/90-day mortality, bacteremia, CRBSI, diarrhea, ICU-acquired infections, infectious complications, pneumonia, UTI and wound infection between two groups (P>0.05 for all). Conclusion: Based on the results of our study, the current evidences suggested that prophylactic administration of probiotic might be utilized as a preventive method for VAP in neonates/children and adults patients who require mechanical ventilation. However, further large, high-quality RCTs are warranted to assess the efficacy and safety of probiotic treatment in critically ill patients, especially for the neonates/children studies and the long-term consequences of this therapy.


Sign in / Sign up

Export Citation Format

Share Document